A Phase II and Pharmacokinetic Study of Weekly 72-h Topotecan Infusion in Patients with Platinum-Resistant and Paclitaxel-Resistant Ovarian Carcinoma

By Rose P.G.   Gordon N.H.   Fusco N.   Fluellen L.   Rodriguez M.   Ingalls S.T.   Hoppel C.L.  

Gynecologic Oncology, Vol. 78, Iss. 2, 2000-08 ,pp. : 228-234

Elsevier

Access to resources Recommend Favorite

A Phase I Study of Paclitaxel, Doxorubicin, and Cisplatin in Patients with Previously Untreated Epithelial Ovarian Cancer

By Naumann R.W.   Alvarez R.D.   Omura G.A.   Segars E.   Kilgore L.C.   Partridge E.E.  

Gynecologic Oncology, Vol. 71, Iss. 3, 1998-12 ,pp. : 450-453

Elsevier

Access to resources Recommend Favorite

A Dose-Escalating Study of Weekly Bolus Topotecan in Previously Treated Ovarian Cancer Patients

By Homesley H.D.   Hall D.J.   Martin D.A.   Lewandowski G.S.   Vaccarello L.   Nahhas W.A.   Suggs C.L.   Penley R.G.  

Gynecologic Oncology, Vol. 83, Iss. 2, 2001-11 ,pp. : 394-399

Elsevier

Access to resources Recommend Favorite

Profound Thrombocytopenia in Previously Treated Patients with Recurrent Ovarian Carcinoma Receiving Topotecan

By Cass I.   Kuo D.Y.   Fields A.L.   Runowicz C.D.   Goldberg G.L.  

Gynecologic Oncology, Vol. 69, Iss. 2, 1998-05 ,pp. : 175-176

Elsevier

Access to resources Recommend Favorite

Weekly administration of topotecan and paclitaxel in pretreated advanced cancer patients: a phase I/II study

By Stathopoulos George   Rigatos Sotiris   Christodoulou Christos   Malamos Nikos   Deliyiannis Filippos   Stathopoulos John   Skarlos Dimosthenis  

Cancer Chemotherapy and Pharmacology, Vol. 54, Iss. 3, 2004-09 ,pp. : 259-264

Springer Publishing Company

Access to resources Recommend Favorite